# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

> **NCT05591079** · PHASE2 · COMPLETED · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 99 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** CS0159 (Linafexor)

## Key facts

- **NCT ID:** NCT05591079
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-10
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2023-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05591079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05591079, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05591079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*